STOCK TITAN
  1. Home
  2. News
  3. NVAX

Novavax, Inc. - NVAX STOCK NEWS

Welcome to our dedicated news page for Novavax (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Novavax's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Novavax's position in the market.

News
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
Rhea-AI Summary
Novavax's COVID-19 vaccine receives Emergency Use Authorization and CDC recommendation, making it the only protein-based non-mRNA option in the U.S. Doses will be available in thousands of locations across the country. The vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants. Adverse reactions include headache, nausea, and fatigue. Seek medical attention for severe allergic reactions or symptoms of myocarditis or pericarditis. Pregnant or breastfeeding individuals should consult with healthcare providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.18%
Tags
covid-19
-
News
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Novavax grants stock options and restricted stock units to Ian Watkins as inducement for employment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Novavax to Participate in Upcoming September Conferences
Rhea-AI Summary
Novavax, Inc. will participate in two upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
conferences
News
Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6
Rhea-AI Summary
Novavax's COVID vaccine candidate induces neutralizing responses to emerging subvariants. It could be the only protein-based non-mRNA vaccine option available in key markets for the fall season.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.51%
Tags
acquisition covid-19
-
News
Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights
Rhea-AI Summary
Novavax announces second quarter financial results and operational highlights, including total revenue of $424 million and net income of $58 million. The company has initiated FDA submission for approval of their updated XBB COVID vaccine and plans to be in the market by September. Novavax has also executed a new strategic partnering agreement with SK bioscience, including an equity investment of $85 million. They have reduced their current liabilities by over $1 billion this year and continue to work towards deriving additional value from their pipeline and technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
earnings
-
News
Novavax to Host Conference Call to Discuss Second Quarter 2023 Financial Results and Operational Highlights on August 8, 2023
Rhea-AI Summary
Novavax, Inc. will report its second quarter 2023 financial results and operational highlights on August 8, 2023, at 8:30 a.m. EDT. The conference call details and replay information are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
conferences earnings
News
Novavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the Prevention of COVID
Rhea-AI Summary
Novavax has been granted full Marketing Authorization (MA) by the European Commission for Nuvaxovid™ (NVX-CoV2373). The vaccine is authorized for use as a primary series in individuals aged 12 and older and as a booster dose in adults aged 18 and older for the prevention of COVID-19. This MA provides a regulatory foundation for future vaccine updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
covid-19
-
News
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
covid-19
-
News
Novavax Announces Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023
Rhea-AI Summary
Novavax, Inc. has adjourned its 2023 Annual Meeting of Stockholders to July 11, 2023. The meeting will be held virtually to vote on proposals described in the Proxy Statement. Proxies representing 49.3% of the shares had been submitted before the adjournment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
none
News
Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
none
Stock NVAX logo
Novavax, Inc.

Nasdaq:NVAX

NVAX Rankings

#2828 Ranked by Market Cap
#5166 Ranked by Stock Gains
N/A Ranked by Dividends

NVAX Stock Data

599.00M
125.20M
4.99%
56.33%
31.37%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Gaithersburg

About NVAX

novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"​), seasonal influenza, pandemic influenza, and ebola virus ("ebov"​). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.